Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
Bibliographic Data
| ID | 15808348 |
|---|---|
| Authors | Yannic Laube (University of Zurich), Miquel Serra‐Burriel (0000-0001-8595-1224, University of Zurich), Miquel Serra-Burriel (University of Zurich), C Glaus (University of Zurich), Camille C E G Glaus (University of Zurich), Kerstin Noëlle Vokinger (0000-0002-6997-7384, University of Zurich, corresponding author) |
| Year | 2024 |
| Volume | 5 |
| Issue | 11 |
| Pages | e244461-e244461 |
| Publication date | 2024-11-27 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | JAMA Health Forum (JOURNAL) |
| Journal identifiers | ISSN: 2689-0186 • E-ISSN: 2689-0186 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/jamahealthforum.2024.4461 |
| PMID | 39601756 |
| OpenAlex | W4404756973 |
| Language | EN |
| References cited | 16 |
The results of this cohort study suggest that, in contrast to Germany and Switzerland, prices of cancer drugs increased substantially post launch in the US. When developing solutions how drug prices can be decreased, launch as well as postlaunch prices require attention from policymakers
Agency (philosophy · Business · Cohort · Drug prices · Economics · Environmental health · Food and drug administration · Public economics · Economic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy · Internal Medicine
| Citation velocity | historical |
|---|---|
| Highly cited | No |